GlassScriptPhysician profile
Stephen J Sladicka
NPI 1487609566
$1,681.75
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $993 · 2020: $138 · 2021: $156 · 2022: $118 · 2023: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $276.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $686.33 | 2019 | |
| Pacira Therapeutics, INC. | $346.90 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $111.90 | 2022-2023 | Xtampza |
| Depuy Synthes Sales INC. | $103.91 | 2019-2021 | |
| Pacira Pharmaceuticals Incorporated | $95.11 | 2022-2023 | Zilretta, Iovera, Exparel |
| Bioventus LLC | $73.20 | 2019-2023 | Exogen Ultrasound Bone Healing System |
| Sanofi-Aventis U.S. LLC | $60.90 | 2021-2023 | |
| Zimmer Biomet Holdings, INC. | $41.65 | 2019-2022 | |
| Baudax Bio INC. | $29.81 | 2020 | |
| Abbvie INC. | $23.05 | 2019 | |
| Boston Scientific Corporation | $20.61 | 2023 | |
| Fidia Pharma USA INC. | $19.35 | 2023 | Hymovis, Triluron |
| Kowa Pharmaceuticals America, INC. | $17.24 | 2022 | |
| Convatec INC. | $16.43 | 2023 | |
| Abbott Laboratories | $15.37 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Assertio Therapeutics, INC. | $12.75 | 2020 | |
| Kinex Medical Company LLC | $7.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Sladicka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.